Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2017 Earnings Presentation
15 slides from Aft Pharmaceuticals's earnings presentation, November 2016
Slide 1: AFT Pharmaceuticals Investor Presentation: H1 FY2017
AFT PHARMACEUTICALS Investor Presentation: H1 FY2017 November 2016
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: H1 FY2017 Highlights
H1 FY2017 HIGHLIGHTS 111 countries that Maxigesic is licensed in – up from 98 at the end of FY2016 6 countries that Maxigesic is launched and sold in 12 number of clinical studies AFT have running in FY2017 $30.5m total income for H1 FY2017* $16.1m available cash as at 30 September 2016 – down from
Slide 4: Maxigesic Update
MAXIGESIC UPDATE Eastern Europe – launch UK – launched pending soon Italy – successful launch and sales increasing significantly Kuwait launch pending soon UAE – sales doubling in second year of sales Singapore – launched in July 2016 Australia – rescheduled to S2 – TV advertising underway – codeine
Slide 5: Maxigesic Tablet Sales Progress to Date
MAXIGESIC TABLET SALES PROGRESS TO DATE Maxigesic Tablets Sold Per Year 80 Millions 70 60 50 40 30 20 10 - FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017* • * Note FY2017 sales estimate is based upon actual first six months (shown in darker blue), current orders and licensee / AFT estimated
Slide 6: Maxigesic Highlights
MAXIGESIC HIGHLIGHTS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries from 98 as at 31 March 2016 to 111 as at 30 September 2016. Clinical Trials for Maxigesic oral dose forms are on track with studies running in
Slide 7: NasoSURF Nebuliser
NASOSURF NEBULISER DRUG DELIVERY AND TREATMENT OF SINUS CONDITIONS A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description chronic sinusitis The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are n
Slide 8: Selected Comments on Local Markets
Selected Comments on Local Markets • NZ Maxigesic defined Pharmacy Market share growing at 18% per annum • NZ Maxigesic Pharmacy Market Share is now 6.5% (Paracetamol and/or Ibuprofen Tablets) • AU sales increased almost twofold over the 3 months post rescheduling 1 July 2017 – weighted distribution
Slide 9: Revenue Growth
REVENUE GROWTH Operating revenue by region, H1 FY2016 – H1 FY2017 H1 FY2016 FY2016 Annual H1 FY2017 • Underlying Australian 20.0 40.0 20.0 growth 17% 15.0 31.2 31.1 13.8 14.6 • Australian launches of 15.0 30.0 15.0 13.5 new over the counter products $m $m $m 10.0 20.0 10.0 • Australian out of stock
Slide 10: Revenue by Region and Channel
REVENUE BY REGION AND CHANNEL Operating revenue by region, H1 FY2017 versus H1 FY2016 • Crystaderm, RestoraNail, NZ$000's Half Year to 30 September H1 FY2017 % of total H1 FY2016 % of total ZoRub and Myconail launched in Australia Australia 14,569 48.9% 13,823 46.8% YoY growth 5.4% • Strong Hospital
Slide 11: Summary P&L
SUMMARY P&L NZ$000's Half Year to 30 September H1 FY2017 % of revenue H1 FY2016 % of revenue Revenue 29,787 29,543 Cost of Sales (19,018) (63.8)% (19,161) (64.9)% • Margins reflect increasing % of higher margin over Gross Profit 10,769 36.2 % 10,382 35.1 % the counter products • 85% of the increase
Slide 12: Summary Balance Sheet
SUMMARY BALANCE SHEET Restated Unaudited Audited as at Restated Unaudited NZ$000's as at 30 Sep 2016 31 March 2016 as at 30 Sep 2015 ASSETS Current assets • Inventory stock build for Inventories 21,451 17,686 15,072 newly launched over the Trade and other receivables 12,748 16,288 12,224 Cash and ot
Slide 13: Summary Cashflow Statement
SUMMARY CASHFLOW STATEMENT NZ$000's, Half Year to 30 September H1 FY2016 H1 FY2015 • Investment into R&D and Net cash (used in)/generated from operating activities (10,270) (3,671) new product launches Net cash (used in) investing activities (686) (332) • Financial flexibility to Net cash generated
Slide 14: Value Drivers
VALUE DRIVERS Product / Market Progress • Launching further OTC products in AU ANZ business • Continuing growth for Maxigesic • Further registrations underway Maxigesic Tabs • Increasing launches in new countries • Further development of a novel formulation • Progress with development of IV, OL & Sa
Slide 15: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Launch Maxigesic in new countries and increase sales Advance Maxigesic registrations in licensed countries and in North America Complete clinical studies of Maxigesic products over FY2017 and FY2018 NasoSURF – complete first clinical trials and first regulatory filings Und
AFT Pharmaceuticals — H1 FY2017 Earnings Presentation on 6ix